Mirati Therapeutics, Inc.

( )
MRTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 1.32%247.031.3%$806.38m
IMMUImmunomedics, Inc. 0.19%85.5211.0%$698.49m
MRNAModerna, Inc. 1.56%70.550.0%$676.85m
NVAXNovavax, Inc. -2.10%111.1896.5%$615.83m
ILMNIllumina, Inc. 1.86%305.463.5%$593.62m
GILDGilead Sciences, Inc. 0.96%62.851.0%$579.64m
REGNRegeneron Pharmaceuticals, Inc. -0.37%571.922.7%$441.73m
BIIBBiogen, Inc. 3.20%282.041.6%$345.71m
VRTXVertex Pharmaceuticals, Inc. -0.17%267.731.9%$340.28m
ALXNAlexion Pharmaceuticals, Inc. -0.99%113.302.0%$282.40m
EXASEXACT Sciences Corp. 2.05%99.7020.7%$262.56m
SRNESorrento Therapeutics, Inc. 5.35%10.151.5%$253.74m
SGENSeattle Genetics, Inc. 3.01%190.516.0%$218.52m
VXRTVaxart, Inc. -5.41%7.000.0%$202.32m
MNTAMomenta Pharmaceuticals, Inc. 0.12%52.463.0%$193.81m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.